A murine monoclonal antibody to the zymogen form of human protein C that blocks protein C activation by thrombin-thrombomodulin both in vitro and in vivo has been humanized using the consensus and resurfacing methods. While the binding of the parent murine antibody to protein C is calcium-dependent (1.5-2-fold decrease in binding without calcium), the humanized antibody exhibited a significant increase in its calcium-dependence (5-fold decrease in binding without calcium). Two exposed human framework residues in the variable light domain of the humanized antibody, aspartic acid L1 and glutamine L3, are responsible for the increase in calcium-dependence.
Introduction
Protein C is a member of the vitamin K-dependent plasma serine proteases and is composed of a heavy chain and a light chain held together by a disulfide bond (Kisiel, 1979; Kisiel and Davie, 1981; Beckmann et al., 1985) . The light chain includes two post-translational modifications: γ-carboxyglutamic acid residues located in the N-terminal portion of the light chain (Kisiel, 1979; Zhang et al., 1992; Christiansen et al., 1994) and erythro-β-hydroxyaspartic acid located in the region of the light chain homologous to epidermal growth factor (Drakenberg et al., 1983) . Both residue types may participate in calcium binding (Amphlett et al., 1981; Sugo et al., 1984; Colpitts et al., 1995) . The heavy chain contains the catalytic serine protease domain.
The zymogen form of human protein C is converted to the active enzyme by the thrombin-thrombomodulin complex in a calcium-dependent reaction (Kisiel and Davie, 1981; Esmon, 1987; Esmon, 1989) . The activation occurs by cleavage of an Arg-Leu peptide bond which is located on the heavy chain. Activated protein C then performs its physiologic anticoagulant role by proteolytic inactivation of the blood coagulation cofactors Va and VIIIa (Kisiel et al., 1977; Vehar and Davie, 1980; Nesheim et al.,1982; Suzuki et al.,1983; Fulcher et al., 1984; Jackson et al., 1994; Kalafatis et al., 1994) .
Previously, a monoclonal antibody, denoted HPC4, to the zymogen form of human protein C was isolated that binds to the activation peptide and blocks protein C activation by thrombin-thrombomodulin both in vitro and in vivo (Taylor et al., 1987) . A subsequent study found that the binding of HPC4 to protein C was calcium-dependent (Stearns et al., 1988) , the first report of an antibody which exhibits a calcium requirement for antibody-antigen binding. Although neither the protein C heavy chain nor the HPC4 antibody separately bind calcium with high affinity, calcium was required for the antibody-protein C heavy chain high affinity interaction. A different anti-human protein C antibody which recognizes the activation site, denoted PC04, did not exhibit calciumdependence (Takahashi et al., 1993) .
As a prelude to investigation of the potential of the HPC4 antibody for therapeutic use, we have humanized the HPC4 antibody. A major limitation in the clinical use of rodent monoclonal antibodies is an anti-globulin response during therapy (Benjamin et al., 1986; Jaffers et al., 1986; Bruggemann et al., 1989) . One method of overcoming this limitation is to 'humanize' the rodent antibody, originally described by Winter and co-workers (Jones et al., 1986; Reichmann et al., 1988) . This technique involves transfer of the complementarity-determining regions (CDRs), which are hypervariable loops involved in antigen binding, from the variable domains of the rodent antibody to a human antibody. Three methods of humanizing antibodies have been utilized. The consensus method (Carter et al., 1992; Presta et al., 1993; Eigenbrot et al., 1994; Werther et al., 1996) utilizes variable light (VL) and variable heavy (VH) domain frameworks derived from the most common amino acid found at each position within a given human subgroup (Kabat et al., 1991) . In the best-fit or homology method (Queen et al., 1989; Co et al., 1991; Sims et al., 1993) a human sequence closest to that of the rodent antibody is used as the framework. In both the consensus and best-fit methods, individual human framework residues may need to be changed to their rodent counterpart in order to attain binding of the humanized antibody which is equivalent (or nearly so) to the original rodent antibody. Only recently have the consensus and best-fit methods been compared (Kolbinger et al., 1993; Sato et al., 1994) and it was found that both methods gave comparable results. In the 'resurfacing' method (Padlan, 1991; Roguska et al., 1994; Roguska et al., 1996) , only the solvent exposed framework residues in VL and VH are changed to human, i.e. the buried, interior residues are left as in the rodent antibody.
The humanized anti-protein C antibody exhibited calciumdependent binding which was significantly increased over that of the murine antibody. Since the murine and humanized antibodies both contained the same residues in the CDRs involved in binding to antigen, we determined that residues in the framework were involved in the calcium-dependence of both the murine and humanized antibodies.
Materials and methods

Cloning of HPC4 cDNA
RNA from approximately 1ϫ10 8 HPC4-hybridoma cells grown in 75 ml T-flasks was prepared and mRNA (polyA ϩ mRNA) was isolated on oligo(dT)-cellulose according to the manufacturer's instruction (Stratagene, San Diego, CA). Approximately 10 µg of polyA ϩ RNA was used to synthesize a doublestranded cDNA library according to the manufacturer's instruction. Using standard molecular biology techniques, the cDNA library was EcoRI linked and ligated to a λgt10 vector which had been linearized with EcoRI. The λgt10 ligation mixture was packaged in vitro (Gigapack II packaging extract, Stratagene), transformed into Escherichia coli C600hflA strain, and plated onto agar plates at high density. The phage plaques were then transfered to Gene Screen Plus filters (New England Nuclear, Boston, MA) and probed with 32 P-labeled DNA fragments derived from constant regions of unrelated immunoglobulin heavy chain (Honjo et al., 1979) and light chain genes (Max et al., 1981) . Several positive clones from heavy and light chain plates were identified. Phage DNA were prepared and the inserts were cleaved using EcoRI restriction enzyme. The clones identified by the heavy chain and the light chain probes gave inserts of~1600 and~800 bp, respectively. The heavy and light chain cDNA fragments were subcloned into the EcoRI site of pUC19 plasmid and sequenced with the universal pUC forward and reverse sequencing primers. The Fab (antigen-binding fragment) portion of HPC4 was cloned by PCR methods into the Immunozap H and L expression vectors (Stratagene) according to the manufacturer's instruction.
Construction of humanized antibody
As in previous humanizations the 'consensus' method was used, employing the consensus human κ subgroup I light chain and consensus human subgroup III heavy chain (Kabat et al., 1991) . The murine HPC4 VL domain is closest in sequence to human κ subgroup I whereas the HPC4 VH domain is closer in sequence to human VH subgroup II (69% identity in framework) than to human VH subgroup III (54% identity). However, human VH subgroup III has been successfully used for several previous humanizations (Carter et al., 1992; Presta et al., 1993; Eigenbrot et al., 1994; Werther et al., 1996) and VH subgroup III (as opposed to subgroup II) was again used in order that the entire set of Genentech humanized antibodies possess the same framework region.
To construct the first Fab variant of humanized HPC4, Fab-1, site-directed mutagenesis (Kunkel, 1985) was performed on a deoxyuridine-containing template containing a human κ subgroup I light chain and human subgroup III heavy chain in a pUC119 based plasmid, previously described (Carter et al., 1992) , to convert the six CDRs to the HPC4 sequence. Plasmids for all other humanized variants were constructed from a DNA template of Fab-1, incorporating new restriction sites for selection into the mutagenic oligonucleotides where possible, and plasmids were transformed into E.coli strain JM101 (Messing, 1979) for preparation of double-and singlestranded DNA.
For each variant both the light and heavy chains were completely sequenced by the dideoxynucleotide method using the Sequenase protocol (US Biochemical, Cleveland, OH). DNA encoding the light and heavy chains was then subcloned into an E.coli Fab expression plasmid (Carter et al., 1992; Presta et al., 1993) using the EcoRV and SphI restriction sites. These expression plasmids were transformed into E.coli strain MM294 (Meselson and Yuan, 1968) , and a single colony was grown in 5 ml 2ϫYT, 100 µg/ml carbenicillin for 5-8 h at 37°C. The 5 ml culture was added to 100 ml AP5, 100 µg/ml carbenicillin and allowed to grow for 16 h in a 500 ml shaker flask at 37°C. AP5 media consists of 1.5 g glucose, 11.0 g Hycase SF, 0.6 g yeast extract (certified), 0.19 g MgSO 4 (anhydrous), 1.07 g NH Cl, 3.73 g KCl, 1.2 g NaCl, 120 ml 1 M triethanolamine, pH 7.4, to 1 liter of water and then sterile filtered through 0.1 mm Sealkeen filter. The culture was centrifuged at 4000 g and the supernatant removed. After freezing for 1 h, the pellet was resuspended in 5 ml cold 10 mM Tris-1 mM EDTA and 50 µl 0.1 M benzamidine (Sigma, St Louis, MO) was added to inhibit proteolysis. After gentle shaking on ice for 1 h, the sample was centrifuged at 10000 g for 15 min. The supernatant was applied to a protein A-Sepharose CL-4B (Pharmacia, Uppsala, Sweden) column (0.5 ml bed volume), washed with 10 ml 10 mM Tris-1 mM EDTA, and eluted with 2.5 ml 100 mM acetic acid, pH 2.8, into 0.5 ml 1 M Tris, pH 8.0. The Fab was then buffer exchanged into phosphate-buffered saline (PBS) using a Centricon-30 (Amicon, Beverly, MA) and concentrated to a final volume of 0.5 ml. SDS-PAGE gels of all Fabs were run to ascertain purity. Fabs-1, 2, 6, 7, 9, 10, 13 and 15 were analyzed directly by liquid chromatography/mass spectrometry to confirm their molecular weight using a Sciex API 3 mass spectrometer.
For quantitation of Fabs, ELISA plates were coated with 2 µg/ml goat anti-human Fab IgG (Organon Teknika, Westchester, PA) in 50 mM carbonate buffer, pH 9.6, overnight at 4°C and then blocked with 0.5% bovine serum albumin (BSA) in PBS at 25°C for 1 h. Standards and serial dilutions of samples in 0.5% BSA, 0.05% Polysorbate 20-PBS were incubated on the plates for 2 h. After washing, bound Fab was detected using peroxidase-labeled goat anti-human Fab (Organon Teknika) and 3,3Ј,5,5Ј-tetramethyl benzidine (Kirkegaard & Perry Laboratories, Gaithersburg, MD) as substrate. Absorbance was read at 450 nm on a V max plate reader (Molecular Devices, Palo Alto, CA). The standard curve was fit using a four-parameter, nonlinear regression curve fitting program developed at Genentech. Data points which fell in the range of the standard curve were used for calculating Fab concentrations.
For generation of human IgG1 versions of humanized HPC4, the heavy and light chains were subcloned separately into previously described pRK plasmids (Gorman et al., 1990) . Appropriate heavy and light chain plasmids were co-transfected into an adenovirus-transformed human embryonic kidney cell line 293 using a high efficiency procedure (Graham et al., 1977; Gorman et al., 1990) . Media was changed to serum free and harvested daily for up to 5 days. Antibodies were purified on protein A-Sepharose CL-4B (Pharmacia) as described for the Fab variants, except that 3 M KCl, 100 mM Tris, pH 8.0, was used instead of 10 mM Tris-1 mM EDTA. The eluted antibody was concentrated by ultrafiltration using Centriprep-30 (Amicon), sterile filtered using Millex-GV (Millipore, Bedford, MA) and stored at 4°C. IgG concentrations were determined by ELISA using goat anti-human Fc IgG (Organon Teknika) for capture and peroxidase-labeled goat anti-human Fc IgG for detection.
Protein C binding assays
For measuring protein C binding by Fabs, ELISA plates were coated with 1 µg/ml human protein C (a gift from Dr Walter Kisiel, University of New Mexico). Serial dilutions of samples in 0.5% BSA, 0.05% Polysorbate 20, 1 mM CaCl 2 -PBS were incubated on the plates and bound Fab was detected using peroxidase-labeled goat anti-human Fab IgG in the same buffer. The concentration of Fab-1 at the midpoint of its titration curve, denoted MidOD50, was calculated (KaleidaGraph, Synergy Software) and used as the standard against which other Fabs were compared. Titration curves of other Fabs were fit with a four parameter nonlinear regression curve fitting program and the concentrations of Fab corresponding to the MidOD50 were divided by the MidOD50 of Fab-1 (Table I) . Binding of IgG variants to protein C was measured on protein C-coated plates using peroxidase-labeled goat antihuman Fc IgG for detection. When determining calciumdependence, calcium was absent from both the sample and the conjugated antibody steps. For comparing the relative protein C binding of IgG chimeras and variants, the concentrations of IgG corresponding to the MidOD50 were compared with that of IgG1-7 (Table III) .
Protein C binding activity of the humanized and the murine antibody were compared using a BIAcore biosensor (Karlsson et al., 1994) . Protein C was coupled to the biosensor chip through primary amine groups. Off-rate kinetics were measured by saturating the chip with antibody (35 µl of 1.2 µM antibody at a flow rate of 20 µl/min) and then switching to buffer. Data points from 0 to 3000 s were used for analysis. On-rate kinetics were measured using twofold serially diluted antibody: 110-890 nM in one experiment and 40-1320 nM in another experiment. Data were analyzed using the BIAcore kinetics evaluation software as described in the Pharmacia Biosensor manual using the same time intervals for the humanized and murine antibodies. The running buffer was 20 mM Tris-HCl, 100 mM NaCl, 1 mM CaCl 2 , 0.05% Polysorbate 20, pH 7.5. At the end of each cycle, bound antibody was removed by injecting 1 µl 50 mM glycine-HCl, 0.15 N NaCl, pH 2.3, at a flow rate of 20 µl/min to regenerate the surface.
Computer graphics models of murine and humanized Fabs
Sequences of the variable light (VL) and variable heavy (VH) domains ( Figure 1 ) were used to construct a computer graphics model of the murine HPC4 VL-VH domains. This model was used to determine which framework residues should be incorporated into the humanized antibody. Models of humanized variants were also constructed to verify correct selection of murine framework residues. Generation of the models was performed as described previously (Carter et al., 1992; Eigenbrot et al., 1993) .
Results
Humanized Fabs
The sequence of Fab-1 VL domain was based on the human VL subgroup κ I consensus sequence with the CDRs, as defined by Kabat et al. (1991) or Chothia et al. (1989) , from murine HPC4. Human VL framework residues at two positions were changed to their murine HPC4 counterparts: MetL4Leu and PheL71Tyr (murine residues are in bold). The VH domain was based on the human subgroup III consensus sequence (Kabat et al., 1991) with the CDRs from murine HPC4. Sequence-based CDR definitions (Kabat et al., 1991) were used for CDR-H2 and CDR-H3; CDR-H1 was defined as a combination of sequence-based and structure-based (Chothia et al., 1989; Kabat et al., 1991) definitions, i.e. extending from residues VH 26-35. Human VH framework residues at several positions were also changed to the murine HPC4 counterparts: AlaH24Leu, ValH37Ile, PheH67Leu, ArgH71Lys, AsnH73Thr, LeuH78Val and AlaH93Val. These murine framework residues were included because of their possible effect on CDR conformation, based on the models of HPC4 and Fab-1.
In order to test whether the model-based sequence of Fab-1 provided correct assignment of the murine framework residues included in the VL and VH domains (as opposed to retaining the human framework residues), we investigated the effect of several of these residues on binding of the humanized Fab to protein C. In the Fab-1 VL domain, the side chains at positions L4 and L33 were the murine residues; these side chains could influence the conformation of CDR-L1 (Figure 2 ). Residue L4 is a framework position; residue L33 is considered a member of CDR-L1 according to the sequence-based definition of CDRs (Kabat et al., 1991) but is considered a framework residue according to the structure-based CDR definition (Chothia et al., 1989) . Both residues were simultaneously changed to the consensus human counterparts and this variant showed significantly reduced binding (Fab-2, Table I ). In contrast, at L71, a position previously ascertained as influencing the conformation of CDR-L1 (Chothia et al., 1989) , changing the murine Tyr to the human Phe showed no effect on binding (Fab-3, Table I ). In the VH domain, a larger number of positions was investigated. Changing the C-terminal half of CDR-H2 back to the human consensus sequence (Fab-4, Table I ) completely abrogated binding. This portion of CDR-H2 is not included in the structural definition of CDRs (Chothia et al., 1989) and in at least one previous humanization this portion of CDR-H2 did not influence binding (Carter et al., 1992) . Based on the models of murine and humanized HPC4, seven human VH framework positions were changed to their murine HPC4 counterparts in Fab-1. These positions could influence CDR conformation or orientation of the VL-VH interface. Position H37 is located at the interface between the VL and VH domains and the murine Ile was included in the humanization; when this residue was changed back to the human Val, binding was reduced by almost 4-fold (Fab-5, Table I ). Framework positions H78, H67 and H93 could influence the conformation of CDR-H1, CDR-H2 and CDR-H3, respectively (Figure 2 ). ValH78Leu (Fab-10) reduced binding by 8-fold, LeuH67Phe (Fab-6) by 5-fold, and ValH93Ala (Fab-11) by 4-fold, underscoring the importance of these three buried residues with respect to the conformations of VH CDRs. Another variant in which three buried framework positions which should not influence CDR conformation were simultaneously changed from the consensus human to murine HPC4 residues had minimal effect on binding .
In the non-CDR loop adjacent to CDR-H1 and CDR-H2, two framework residues, both exposed to solvent, also affected binding. Position H71 has been previously shown to influence the conformation of CDR-H2 (Chothia et al., 1989; Tramontano et al., 1990) and hence the murine Lys was included in Fab-1. However, changing the murine LysH71 to the human consensus ArgH71 effected a slight (1.7-fold) improvement in binding (Fab-7) . If one peruses the consensus sequences of VH domains, either murine or human, H71 and H73 are often linked, i.e. they form a sequence pair that characterizes VH subgroups. For example, human VH subgroup II uses LysH71-ThrH73, human VH subgroup III uses ArgH71-Asn(or Asp)H73, murine VH subgroup IB uses LysH71-AsnH73 and murine subgroup IIA uses ValH71-LysH73 (Kabat et al., 1991) . In Fab-8, both positions H71 and H73 were changed to human, i.e. LysH71Arg and ThrH73Asn, resulting in a small decrease in binding. Since changing LysH71Arg alone improved binding (Fab-7), the reduction in binding of Fab-8 can be attributed to the negative effect of changing ThrH73Asn. Hence, of the H71:H73 pair, position H71 was retained as human and most likely influences the conformation of CDR-H1 and/or CDR-H2. In contrast, at position H73 the murine Thr was optimal and is positioned so that it may be making direct contact with the protein C (Figure 2) .
Another method of humanization referred to as 'resurfacing' (Padlan, 1991; Roguska et al., 1994; Roguska et al., 1996) was also evaluated. For this variant, all buried residues in both the VL and VH domains were the murine residues (Fab-13, Table I ). Compared with Fab-1, it includes an additional six murine residues in the VL domain and an additional four murine residues in the VH domain. This variant bound only about twofold better than Fab-1. In order to determine whether the light chain or the heavy chain murine buried residues were providing the twofold improvement in binding, two additional Fabs were generated. In Fab-14 the Fab-1 heavy chain was combined with the Fab-13 light chain and in Fab-15 the Fab-1 light chain was combined with the Fab-13 heavy chain. Surprisingly, neither of these Fabs bound better than Fab-1 ( Table I ), suggesting that the murine interiors of the light and heavy chains may have influenced the VL-VH interface in Fab-13.
Humanized full-length IgG1
Murine HPC4 bound to protein C 20-30-fold better than the best humanized Fabs (compare Fab-7, Fab-9 and HPC4IgG, Table I ). However, differences in avidity between the humanized Fabs and full-length murine HPC4 could contribute to this difference as well as the requirement for different analytical reagents. Hence, Fab-7 was transferred to a human IgG1 to generate IgG1-7 and tested for binding to protein C using a BIACore biosensor (Pharmacia). For IgG1-7, both k on and k off are slightly faster compared with the murine HPC4 antibody and the apparent K d value is reduced only 1.6-fold (Table II) .
Determination of calcium-binding site on IgG1-7
A murine/human chimera IgG, denoted as mLmH, was constructed in which the VL and VH domains on IgG1-7 were replaced with the entire VL and VH domains from murine HPC4. The humanized IgG1-7 was more calcium-dependent than mLmH, exhibiting a 5.2-fold reduction in binding in the absence of calcium compared with 1.4-fold for mLmH (Table  III , Figure 3 ). To determine if the increased calcium-dependence was a function of changes in the VL domain, VH domain or both, two additional murine/humanized chimeras were generated. In the first, the mLmH light chain was co-expressed with the IgG1-7 heavy chain (denoted as mL7H); this chimera contains a murine VL domain and a humanized VH domain. In the second, the mLmH heavy chain was co-expressed with the IgG1-7 light chain (denoted as 7LmH); this chimera contains a humanized VL domain and a murine VH domain. The binding and calcium-dependence of these proteins showed that the increased calcium-dependence was a function only of the humanized VL domain (Table III) . The sequences of the humanized and murine HPC4 VL domains were compared to ascertain whether side chains in the humanized HPC4 which differed from the murine antibody could function as calcium ligands, i.e. Asp, Asn, Glu, Gln. There are six differences between the two sequences: GlnL1Asp, IleL3Gln, GluL17Asp, AlaL55Glu, PheL70Asp and GluL79Gln. Previous studies on the interaction of HPC4 with human protein C had shown that the calcium-binding site incorporated residues from both proteins (Stearns et al., 1988) . If only VL side chains near the CDRs are considered as potential calcium-binding participants, then the list is narrowed to GlnL1Asp, IleL3Gln, AlaL55Glu and PheL70Asp. Variants of IgG1-7 were constructed in which each of the human residues at these four positions was changed to its counterpart in murine HPC4. IgG1-25 (AspL1Gln), IgG1-26 (GlnL3Ile), IgG1-27 (AspL70Phe) and IgG1-28 (GluL55Ala) showed the same calcium-dependence as IgG1-7 and 7LmH (Table III, Figure 4 ). In contrast, IgG1-24 (AspL1Gln/GlnL3Ile) exhibited the same calcium-dependence as found in mLmH and mL7H (Table III, Figure 4 ). Comparing IgG1-24, IgG1-25 and IgG1-26 suggests that either Asp at position L1 or Gln at position L3 can increase the calcium-dependence. Only when both residues are murine, i.e. GlnL1 and IleL3, is the calciumdependence similar to the murine antibody. Note also that changing residue L1 from Asp to Gln improved the binding of IgG1-7 both in the presence and absence of calcium  Table III) .
Replacing the murine neutral GlnL1 with the negativelycharged AspL1 in the humanized antibody may have introduced a better calcium-binding ligand. The presence of the GlnL3 side chain in the humanized antibody could augment the calcium-binding by either providing another calcium ligand (the Oε1 atom of the Gln side chain) or by stabilizing a specific conformation of AspL1 via formation of a hydrogen bond from GlnL3 Nε2 to AspL1 Oδ.
Importance of Asp residues in CDR-H2 and CDR-H3
CDR-H2 and CDR-H3 each contain three Asp residues ( Figure  4 ). Each of these was individually changed to Ala to determine their importance with respect to binding protein C. Table IV shows that AspH54Ala (CDR-H2) and AspH100aAla (CDR-H3) reduced binding by about 300-and 1000-fold, respectively. In addition, AspH56Ala (CDR-H2) and AspH97Ala (CDR-H3) reduced binding by greater than 10-fold. Two other Asp residues each increased binding twofold when changed to Ala: AspH55 in CDR-H2 and AspH72. The latter is in the non-CDR loop adjacent to CDR-H1 and CDR-H2 and was evaluated since the two residues adjacent to it, i.e. at positions H71 and H73, affected binding (Fab-7 and Fab-8, Table I ). Because the AspH54Ala and AspH100aAla variants bound poorly even in the presence of calcium, it was not possible to discern whether these two Asp residues were involved in binding calcium or in direct interaction with protein C.
Discussion
The highest affinity humanized variants of the murine antiprotein C antibody, HPC4, contained the murine CDRs as well as several murine framework residues. Most of the murine framework residues in the humanized antibody were included based on computer graphics models of the murine and humanized antibodies. In the VL domain, murine residues at positions L4 and L71 were included, but evaluation of murine/human changes showed that only L4 had an effect on binding (Table  I) . The residue at L4 most likely affects the conformation of CDR-L1. In the VH domain, seven murine framework residues were initially included based on the models: residues H24, H37, H67, H71, H73, H78 and H93. All except residue H71 reduced binding when changed to their human counterpart (Table I) . H37 is at the VL-VH interface while H67, H78 and H93 are buried inside VH and probably influence the conformations of CDR-H2, CDR-H1 and CDR-H3, respectively (Figure 2) . None of these three buried residues was included in the list of important framework residues affecting CDR conformation compiled previously (Chothia et al., 1989) . Residue H71 was included as murine since this position has previously been reported as important for conformation of CDR-H2 (Chothia et al., 1989; Tramontano et al., 1990) . However, for this particular antibody the human residue (Arg) was preferred over the murine residue (Lys) by twofold (Table I ). In contrast, at H73 the murine residue was preferred (compare Fab-7 and Fab-8, Table I ). The loop containing H73 is adjacent to CDR-H1 and CDR-H2 (Figure 2 ) and the importance of residues in this non-CDR loop for antigen binding has been demonstrated previously (Carter et al., 1992; Eigenbrot et al., 1994; Werther et al., 1996) , suggesting that this loop may sometimes function as a seventh CDR. One additional buried residue in VH was evaluated at H12; changing this residue from human to murine effected only a minor improvement in binding (compare Fab-7 and Fab-9, Table I ). Hence, of the murine framework residues included in the final humanized antibody (Fab-7), all except that at H71 were predicted by the model.
In this study, the 'resurfaced' variant (Fab-13) and the optimal consensus variant (Fab-7) showed equivalent binding (Table I) . However, the optimal consensus variant contains 10 fewer murine residues than the 'resurfaced' variant. A previous comparison of an anti-IgE antibody humanized using the 'consensus' and 'resurfacing' methods also showed equivalent binding and in that case the 'consensus' humanized antibody also had 10 fewer murine residues than the 'resurfaced' humanized antibody .
HPC4 is the first, and to our knowledge the only, antibody reported which exhibits a calcium requirement for antibodyantigen binding. The humanization of this murine anti-human protein C antibody was unusual in that the humanized form showed a significant increase in calcium-dependence for binding compared with the murine antibody. Since both the murine and humanized antibodies contained identical CDR residues, we investigated the possibility that human framework residues were involved in the increased calcium-dependence of the humanized antibody. Evaluation of antibodies in which humanized light chain was matched with murine chimeric heavy chain and in which murine chimeric light chain was matched with humanized heavy chain showed that the increased calcium-dependence of the humanized variant resided solely in the light chain. Further evaluation of framework residues in the VL domain implicated AspL1 and GlnL3 in the humanized variant as the human framework residues involved in the increased calcium-dependence (Table III) .
HPC4 binds to the activation site of the zymogen form of 327 protein C (Taylor et al., 1987; Stearns et al., 1988) . The human protein C activation sequence includes several Asp, Glu and Gln residues which could participate in formation of a calciumbinding site with residue L1 of the humanized or murine HPC4 antibodies. Studies on the acidic residues in the activation peptide of protein C have shown that Asp167 and Asp172 of protein C (P3 and P3Ј, respectively, of the thrombin proteolytic cleavage site) are involved in calcium-dependent inhibition of protein C activation by thrombin (Rezaie and Esmon, 1992; Friedrich et al., 1994) . While there is no direct evidence from the current study that these two aspartic acid residues are involved in the calcium-binding site with HPC4, it does show that calcium-binding is important in this region of protein C. Though the humanized HPC4 antibody does show increased calcium-dependence, its binding in the presence of calcium is less than twofold down from the parent murine antibody (Table  II) . Since calcium should not be a limiting factor in vivo, the humanized antibody can be evaluated as a possible therapeutic in diseases where prevention of the activation of protein C is desirable. While a humanized variant in which the calciumdependence is identical to that of the murine parent, e.g. IgG1-24 (Table III) , could be used, residues L1 and L3 are exposed to solvent and thus could possibly effect an anti-antibody response.
